Synergy between IL-6 and TGF-β signaling promotes FOXP3 degradation

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 7, 2012, Pages 626-633

  Gao, Zhimei ^a,b   Gao, Yayi ^b   Li, Zhiyuan ^b   Chen, Zuojia ^b   Lu, Daru ^a   Tsun, Andy ^b   Li, Bin ^b  

^a FUDAN UNIVERSITY   (China)

^b INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

FOXP3; IL 6; Instability; proteasome; TGF ; Treg

Indexed keywords

BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUPEPTIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BIOSYNTHESIS; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; INFLAMMATION; LEUKEMIA CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN DEGRADATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

CELLULAR MICROENVIRONMENT; DOWN-REGULATION; DRUG SYNERGISM; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INFLAMMATION; INTERLEUKIN-6; JURKAT CELLS; LEUPEPTINS; PROTEOLYSIS; RECEPTORS, INTERLEUKIN-6; RNA, MESSENGER; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84866018476     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Zhu J and Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008; 112: 1557-1569.
2. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA and Cua DJ. IL-23 drives a pathogenic T cell population that induces autoim mune inflammation. J Exp Med 2005; 201: 233-240.
3. Fontenot JD, Gavin MA and Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
4. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G and Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886.
5. Lan Q, Fan H, Quesniaux V, Ryffel B, Liu Z and Zheng SG. Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases? J Mol Cell Biol 2012; 4: 22-28.
6. Zheng SG, Gray JD, Ohtsuka K, Yamagiwa S and Horwitz DA. Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors. J Immunol 2002; 169: 4183-4189.
7. Mantel PY, Ouaked N, Ruckert B, Karagiannidis C, Welz R, Blaser K and Schmidt-Weber CB. Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol 2006; 176: 3593-3602.
8. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL and Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
9. Kong N, Lan Q, Chen M, Wang J, Shi W, Horwitz DA, Quesniaux V, Ryffel B, Liu Z, Brand D, Zou H and Zheng SG. Antigen-specific TGF-beta-induced regulatory T cells but not natural Tregs ameliorate autoimmune arthritis by shifting the balance of Th17 toward Treg cells. Arthritis Rheum 2012.
10. Xiao S, Jin H, Korn T, Liu SM, Oukka M, Lim B and Kuchroo VK. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 2008; 181: 2277-2284.
11. Zhou X, Kong N, Wang J, Fan H, Zou H, Horwitz D, Brand D, Liu Z and Zheng SG. Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J Immunol 2010; 185: 2675-2679.
12. Lu L, Ma J, Li Z, Lan Q, Chen M, Liu Y, Xia Z, Wang J, Han Y, Shi W, Quesniaux V, Ryffel B, Brand D, Li B, Liu Z and Zheng SG. All-trans retinoic acid promotes TGF-beta-induced Tregs via histone modification but not DNA demethylation on Foxp3 gene locus. PLoS One 2011; 6: e24590.
13. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A and Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942-949.
14. O'Garra A, Stockinger B and Veldhoen M. Differentiation of human T(H)-17 cells does require TGF-beta! Nat Immunol 2008; 9: 588-590.
15. Manel N, Unutmaz D and Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008; 9: 641-649.
16. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM and Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179-189.
17. Qin H, Wang L, Feng T, Elson CO, Niyongere SA, Lee SJ, Reynolds SL, Weaver CT, Roarty K, Serra R, Benveniste EN and Cong Y. TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol 2009; 183: 97-105.
18. Dominitzki S, Fantini MC, Neufert C, Nikolaev A, Galle PR, Scheller J, Monteleone G, Rose-John S, Neurath MF and Becker C. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol 2007; 179: 2041-2045.
19. Ciechanover A and Schwartz AL. The ubiquitinproteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 1998; 95: 2727-2730.
20. D'Andrea A and Pellman D. Deubiquitinating enzymes: a new class of biological regulators. Crit Rev Biochem Mol Biol 1998; 33: 337-352.
21. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; 443: 780-786.
22. Schubert LA, Jeffery E, Zhang Y, Ramsdell F and Ziegler SF. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 2001; 276: 37672-37679.
23. Fontenot JD, Rasmussen JP, Gavin MA and Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-1151.
24. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT, Laurence A, Robinson GW, Shevach EM, Moriggl R, Hennighausen L, Wu C and O'Shea JJ. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 2007; 109: 4368-4375.
25. Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M and Drobyski WR. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009; 114: 891-900.
26. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M and Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448: 484-487.
27. Neufert C, Becker C, Wirtz S, Fantini MC, Weigmann B, Galle PR and Neurath MF. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol 2007; 37: 1809-1816.
28. Mantel PY, Kuipers H, Boyman O, Rhyner C, Ouaked N, Ruckert B, Karagiannidis C, Lambrecht BN, Hendriks RW, Crameri R, Akdis CA, Blaser K and Schmidt-Weber CB. GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007; 5: e329.
29. Zheng SG, Wang J and Horwitz DA. Cutting edge: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J Immunol 2008; 180: 7112-7116.
30. Lu L, Wang J, Zhang F, Chai Y, Brand D, Wang X, Horwitz DA, Shi W and Zheng SG. Role of SMAD and non-SMAD signals in the development of Th17 and regulatory T cells. J Immunol 2010; 184: 4295-4306.
31. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel R, Hennighausen L, Shevach EM and O'Shea JJ. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007; 26: 371-381.
32. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M and Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317: 256-260.
33. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ and Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121-1133.
34. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, Watowich SS, Tian Q, Jetten AM and Dong C. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008; 28: 29-39.
35. Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A and Rudensky AY. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009; 326: 986-991.
36. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF and Littman DR. TGF-betainduced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453: 236-240.
37. Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M, Takaesu G, Hori S, Yoshimura A and Kobayashi T. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem 2008; 283: 17003-17008.
38. Xu L, Kitani A, Fuss I and Strober W. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGFbeta. J Immunol 2007; 178: 6725-6729.
39. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, van Beekum O, Brenkman AB, Hijnen DJ, Mutis T, Kalkhoven E, Prakken BJ and Coffer PJ. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010; 115: 965-974.
40. Samanta A, Li B, Song X, Bembas K, Zhang G, Katsumata M, Saouaf SJ, Wang Q, Hancock WW, Shen Y and Greene MI. TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci USA 2008; 105: 14023-14027.
41. Gao W, Thompson L, Zhou Q, Putheti P, Fahmy TM, Strom TB and Metcalfe SM. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle 2009; 8: 1444-1450.